Year: 2024

Avid Closes Acquisition of Wolftech

Written by Customer Service on November 5, 2024. Posted in Mergers And Acquisitions.

Broadcast technology leaders complete acquisition process, joining forces to empower digital-first, story-driven newsroom collaborationAvid x Wolftech logosAvid x WolftechBURLINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) — Avid®, the global leader in software solutions for professional media production, today announced it has completed the acquisition of Wolftech Broadcast Solutions, the industry leader in cloud-based multiplatform news planning, production and publishing solutions. The acquisition enables Avid to combine its digital-first, end-to-end media solution with Wolftech’s expertise in story-centric workflow management. News organizations will be able to increase efficiency and accelerate story delivery through enhanced remote collaboration and multiplatform amplification. Avid CEO Wellford Dillard stated:...

Interim report of Copenhagen Airports A-S (CPH) for the period 1 January – 30 September 2024

Written by Customer Service on November 5, 2024. Posted in Earnings Releases And Operating Results.

The Board of Directors has today approved the interim report for the period 1 January – 30 September 2024.COPENHAGEN AIRPORTS A/S P.O. Box 74 Lufthavnsboulevarden 6 DK-2770 KastrupContact: Rasmus Lund CFOTelephone: +45 3231 3231 E-mail: cphpresse@cph.dk www.cph.dk CVR nr. 14 70 72 04AttachmentQ3 2024 Report of Copenhagen Airports A-S

Navios Maritime Partners L.P. Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2024

Written by Customer Service on November 5, 2024. Posted in Earnings Releases And Operating Results.

Revenue:$ 340.8 million for Q3 2024 $1,001.5 million for 9M 2024Net Income:$ 97.8 million for Q3 2024 $ 272.6 million for 9M 2024Earnings per common unit:$ 3.20 for Q3 2024 $ 8.87 for 9M 2024Net cash from operating activities:$ 142.6 million for Q3 2024 $ 368.6 million for 9M 2024EBITDA:$ 196.6 million for Q3 2024 $ 559.8 million for 9M 2024Returning capital to unitholders:351,125 common units repurchased in 2024 (through October 29, 2024) for $18.3 million $0.05 per unit cash distribution for Q3 2024; $0.20 per unit annualizedSales and purchases in Q3 – Q4 2024 QTD:$ 212.0 million acquisition of two newbuilding containerships $ 25.9 million gross sale proceeds from sale of two dry bulk vessels Three newbuilding vessels delivered$3.9 billion contracted revenue as...

Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights

Written by Customer Service on November 5, 2024. Posted in Earnings Releases And Operating Results.

Clinical data update from the NXP800 Phase 1b study expected this month; NXP800 granted Orphan Drug Designation for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers NXP900 Phase 1a dose escalation study progressing as planned, 4 escalation cohorts completed with no DLTs, dose escalation continuesFORT LEE, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the third quarter of 2024 and provided an update on recent business progress. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis,...

Colliers Reports Third Quarter Results

Written by Customer Service on November 5, 2024. Posted in Earnings Releases And Operating Results.

Solid growth across all service lines and segments Re-aligned operating segments to better reflect value and growth Third quarter and year to date operating highlights: Three months ended Nine months ended September 30 September 30(in millions of US$, except EPS) 2024 2023 2024 2023 Revenues $ 1,179.1 $ 1,056.0 $ 3,320.4 $ 3,100.0 Adjusted EBITDA (note 1) 154.6 144.9 419.0 396.6 Adjusted EPS (note...

Sotera Health Reports Third-Quarter and Year-to-Date 2024 Results

Written by Customer Service on November 5, 2024. Posted in Earnings Releases And Operating Results.

Q3 2024 net revenues of $285 million increased 8.5%, compared to Q3 2023 Q3 2024 net income of $17 million or $0.06 per diluted share, compared to net loss of $14 million or $0.05 per diluted share in Q3 2023 Q3 2024 Adjusted EBITDA(1) of $146 million increased 9.0%, compared to Q3 2023 Q3 2024 Adjusted EPS(1) of $0.17 increased $0.01 per diluted share, compared to Q3 2023 Reaffirming 2024 Net Revenue and Adjusted EBITDA outlook rangesCLEVELAND, Nov. 05, 2024 (GLOBE NEWSWIRE) — Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the three and nine months ended September 30, 2024. Third-quarter 2024 net revenues increased 8.5%...

Centerra Gold Announces TSX Acceptance of Renewed Normal Course Issuer Bid

Written by Customer Service on November 5, 2024. Posted in Public Companies.

TORONTO, Nov. 05, 2024 (GLOBE NEWSWIRE) — Centerra Gold Inc. (TSX: CG) (NYSE: CGAU) (“Centerra” or the “Company”) is pleased to announce that the Toronto Stock Exchange (“TSX”) has accepted its renewal of a normal course issuer bid (“NCIB”) to purchase for cancellation up to an aggregate of 18,800,929 common shares in the capital of the Company (“Common Shares”) during the twelve-month period commencing on November 7, 2024 and ending on November 6, 2025, representing approximately 8.9% of Centerra’s total issued and outstanding Common Shares, or 10% of the public float. As of November 5, 2024, Centerra had 211,321,285 issued and outstanding Common Shares. Under the NCIB, daily purchases would be limited to 213,230 Common Shares, other than purchases made under block purchase exemptions. Once the NCIB is commenced, the exact timing...

Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates

Written by Customer Service on November 5, 2024. Posted in Earnings Releases And Operating Results.

BURLINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the third quarter of 2024 ending September 30, 2024. Roluperidone NDA Update As announced in February 2024, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to our New Drug Application (NDA) for roluperidone (f/k/a MIN-101) for the treatment of negative symptoms in patients with schizophrenia. Interactions with the FDA continue with the goal of addressing questions raised in the CRL. Third Quarter 2024 Financial Results Research and development (R&D) expense: For the three months ended September 30, 2024...

Hillman Reports Third Quarter 2024 Results

Written by Customer Service on November 5, 2024. Posted in Earnings Releases And Operating Results.

CINCINNATI, Nov. 05, 2024 (GLOBE NEWSWIRE) — Hillman Solutions Corp. (Nasdaq: HLMN) (the “Company” or “Hillman”), a leading provider of hardware products and merchandising solutions, reported financial results for the thirteen and thirty-nine weeks ended September 28, 2024. Third Quarter 2024 Highlights (Thirteen weeks ended September 28, 2024)Net sales decreased (1.4)% to $393.3 million compared to $398.9 million in the prior year quarter Net income totaled $7.4 million, or $0.04 per diluted share, compared to $5.1 million, or $0.03 per diluted share, in the prior year quarter Adjusted diluted EPS1 was $0.16 per diluted share compared to $0.11 per diluted share in the prior year quarter Adjusted EBITDA1 totaled $72.6 million compared to $66.8 million in the prior year quarter Acquired Intex DIY, a leading supplier of wiping...

Bioventus Reports Third Quarter Financial Results

Written by Customer Service on November 5, 2024. Posted in Earnings Releases And Operating Results.

Q3 Revenue Advanced by 15.0%, Fourth Straight Quarter of Double Digit Organic* Growth Q3 Gross Margin Expanded 200 bps Q3 Cash from Operations of $10.3 million, an Increase of $18.6 million Compared to Previous YearDURHAM, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 28, 2024. “We delivered strong financial results in the third quarter, including double-digit organic growth and significantly increased cash flow,” said Rob Claypoole, Bioventus President and Chief Executive Officer. “We remain focused on successfully executing on our strategic priorities to accelerate revenue growth, enhance profitability, and reduce...

Year: 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals